{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:05:13Z","timestamp":1790186713641,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.diabres.2026.113512","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:50:59Z","timestamp":1787669459000},"page":"113512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial"],"prefix":"10.1016","volume":"240","author":[{"given":"Das","family":"Sambit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Das Bijay","family":"Ketan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahoo","family":"Devadarshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choudhury Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Dayanidhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nath","family":"Preetam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padhee","family":"Sourav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prusty","family":"Binod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agarwal","family":"Vishal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahu Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113512_b0005","unstructured":"IDF Diabetes Atlas [Internet]. 11th Edition. Belgium: International Diabetes Federation.; 2025 [cited 2025 Dec 10]. 130 p. Available from: https:\/\/diabetesatlas.org."},{"issue":"8","key":"10.1016\/j.diabres.2026.113512_b0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113512_b0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.diabres.2026.113512_b0020","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.diabres.2026.113512_b0025","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2026.113512_b0030","doi-asserted-by":"crossref","unstructured":"Dua A, Kumari R, Singh M, Kumar R, Pradeep S, Ojesina AI, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front Med [Internet]. 2025 Aug 14 [cited 2025 Dec 6];12. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2025.1618275\/full.","DOI":"10.3389\/fmed.2025.1618275"},{"issue":"18","key":"10.1016\/j.diabres.2026.113512_b0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin Sci"},{"issue":"3","key":"10.1016\/j.diabres.2026.113512_b0040","first-page":"170","article-title":"Molecular mechanisms involved in hepatic steatosis and insulin resistance","volume":"2","author":"Matsuzaka","year":"2011","journal-title":"J DiabetesInvestig"},{"key":"10.1016\/j.diabres.2026.113512_b0045","unstructured":"Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications [Internet]. [cited 2025 Dec 6]. Available from: https:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2025.0644."},{"issue":"9","key":"10.1016\/j.diabres.2026.113512_b0050","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70281","article-title":"Limitations of guideline\u2010recommended risk stratification in identifying MASLD patients for novel drug treatments","volume":"45","author":"Franck","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.diabres.2026.113512_b0055","doi-asserted-by":"crossref","unstructured":"Dawod S, Brown K. Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front Med [Internet]. 2024 Nov 13 [cited 2025 Dec 6];Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2024.1499013\/full.","DOI":"10.3389\/fmed.2024.1499013"},{"key":"10.1016\/j.diabres.2026.113512_b0060","unstructured":"Bureau EN. Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease [Internet]. Express Pharma. 2020 [cited 2025 Dec 6]. Available from: https:\/\/www.expresspharma.in\/amp\/zydus-gets-dcgi-approval-for-saroglitazar-mg-to-treat-non-alcoholic-fatty-liver-disease\/."},{"key":"10.1016\/j.diabres.2026.113512_b0065","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA [Internet]. [cited 2025 Dec 6]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"issue":"6","key":"10.1016\/j.diabres.2026.113512_b0070","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.diabres.2026.113512_b0075","article-title":"Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review","volume":"17","author":"Rabizadeh","year":"2019","journal-title":"Int J Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2026.113512_b0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/br.2024.1904","article-title":"Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes","volume":"22","author":"Gao","year":"2024","journal-title":"Biomed Rep"},{"issue":"10","key":"10.1016\/j.diabres.2026.113512_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2026.113512_b0090","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes ResClin Pract"},{"issue":"6","key":"10.1016\/j.diabres.2026.113512_b0095","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11606-008-0594-0","article-title":"Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race\/ethnic groups","volume":"23","author":"Frank","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113512_b0100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-024-10758-3","article-title":"Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Weng","year":"2025","journal-title":"Hepatol Int"},{"issue":"389","key":"10.1016\/j.diabres.2026.113512_b0105","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"4","author":"Lin","year":"2025","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.diabres.2026.113512_b0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatol Baltim Md"},{"issue":"5","key":"10.1016\/j.diabres.2026.113512_b0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatol Baltim Md"},{"issue":"1","key":"10.1016\/j.diabres.2026.113512_b0120","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.diabres.2026.113512_b0125","article-title":"Diagnostic accuracy of transient elastography in MASLD is independent of MRI-PDFF steatosis in a multicenter study","volume":"7","author":"Masrour","year":"2025","journal-title":"JHEP Rep"},{"issue":"26","key":"10.1016\/j.diabres.2026.113512_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40360-025-00898-z","article-title":"Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis","volume":"12","author":"Fan","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113512_b0135","article-title":"Weight-centric treatment of type 2 diabetes mellitus","volume":"24","author":"Ghusn","year":"2022","journal-title":"Obes Pillars"},{"issue":"388","key":"10.1016\/j.diabres.2026.113512_b0140","article-title":"Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial","volume":"22","author":"Liu","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.diabres.2026.113512_b0145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic fatty liver disease and obesity treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr Obes Rep"},{"issue":"8","key":"10.1016\/j.diabres.2026.113512_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/metabo15080536","article-title":"SGLT2 inhibitors: multifaceted therapeutic agents in cardiometabolic and renal diseases","volume":"15","author":"Checa-Ros","year":"2025","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.diabres.2026.113512_b0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.31083\/j.fbl2807134","article-title":"SGLT-2 inhibitors for non-alcoholic fatty liver disease: a review","volume":"28","author":"Zhang","year":"2023","journal-title":"Front Biosci-Landmark"},{"key":"10.1016\/j.diabres.2026.113512_b0160","doi-asserted-by":"crossref","unstructured":"Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol [Internet]. 2021 June 17 [cited 2025 Dec 7];12. Available from: https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2021.635556\/full.","DOI":"10.3389\/fendo.2021.635556"},{"issue":"489","key":"10.1016\/j.diabres.2026.113512_b0165","article-title":"Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1\/AMPK\/PGC1\u03b1\/FoxO1 axis","volume":"1","author":"Hassan","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"23","key":"10.1016\/j.diabres.2026.113512_b0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives","volume":"19","author":"Morciano","year":"2024","journal-title":"CardioVasc Diabetol"},{"issue":"14","key":"10.1016\/j.diabres.2026.113512_b0175","article-title":"The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"27","author":"Liu","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabres.2026.113512_b0180","doi-asserted-by":"crossref","unstructured":"Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kj\u00e6r MS, et al. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health, Eur [Internet]. 2024 Jan 1 [cited 2025 Dec 7];36. Available from: https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(23)00199-0\/fulltext.","DOI":"10.1016\/j.lanepe.2023.100780"},{"key":"10.1016\/j.diabres.2026.113512_b0185","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s40001-024-02032-x","article-title":"Diagnostic performance of new BAST score versus FIB-4 index in predicating of the liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease","volume":"29","author":"Helal","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.diabres.2026.113512_b0190","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Dec 7]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576405\/."},{"issue":"11","key":"10.1016\/j.diabres.2026.113512_b0195","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.2337\/dc25-1319","article-title":"India-specific consensus on MASLD in type 2 diabetes: bridging global guidelines to local realities","volume":"48","author":"Kumar","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:23:56Z","timestamp":1790184236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0168822726004328"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113512","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113512"}}